tradmap

PHAT Earnings Phathom Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$5 -$3 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $88M $175M 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$255M -$128M $0 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$2 -$1 $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
EPS
Revenue (quarterly)
$0 $42M $85M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Revenue
Net income (quarterly)
-$94M -$47M $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Net income

Reported EPS history

1–26 of 26
Q3 20262026-09-30-0.162026-10-2910-Q
Q2 20262026-06-30-0.212026-07-3010-Q
Q1 20262026-03-31-0.372026-04-3010-Q
Q4 2025 (derived)2025-12-31-0.262026-02-2610-K
FY 20252025-12-31-3.032026-02-2610-K
Q3 20252025-09-30-0.412025-10-3010-Q
Q2 20252025-06-30-1.052025-08-0710-Q
Q1 20252025-03-31-1.312025-05-0110-Q
Q4 2024 (derived)2024-12-31-0.992025-03-0610-K
FY 20242024-12-31-5.292025-03-0610-K
Q3 20242024-09-30-1.322024-11-0710-Q
Q2 20242024-06-30-1.562024-08-0810-Q
Q1 20242024-03-31-1.422024-05-0910-Q
Q4 2023 (derived)2023-12-31-1.442024-03-0710-K
FY 20232023-12-31-3.932024-03-0710-K
Q3 20232023-09-30-0.762023-11-0910-Q
Q2 20232023-06-30-0.842023-08-1010-Q
Q1 20232023-03-31-0.892023-05-1010-Q
Q4 2022 (derived)2022-12-31-1.332023-02-2810-K
FY 20222022-12-31-5.052023-02-2810-K
Q3 20222022-09-30-1.322022-11-0810-Q
Q2 20222022-06-30-1.332022-08-0210-Q
Q1 20222022-03-31-1.07——
FY 20212021-12-31-3.89——
Q3 20212021-09-30-0.98——
Q2 20212021-06-30-1.00——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.